Preliminary study of testing circulating tumor cells in patients with renal cell carcinoma by Cell-search System
10.3760/cma.j.issn.1000-6702.2013.10.005
- VernacularTitle:肾细胞癌外周血循环肿瘤细胞检测方法的初步探讨
- Author:
Yushi ZHANG
;
Hanzhong LI
;
Chun ZHOU
- Publication Type:Journal Article
- Keywords:
Circulating tumor cells;
Renal cell carcinoma;
Cell-search System;
Anti-CK8/18/19 antibodies
- From:
Chinese Journal of Urology
2013;34(10):738-741
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the feasibility and to improve the efficiency of testing circulating tumor cells(CTC)in patients with renal cell carcinoma by Cell-search System(CSS).Methods Eight patients with renal cell carcinoma hospitalized in the PUMC urology department for further clinical evaluation in Jan.to Jun.2012 were enrolled in this study.There were 5 males and 3 females with mean age of 64 (57-70)years.There were 2 cases in clinical stage T3N0M0 and 6 cases in T4N0M1;3 cases were treated with radical nephrectomy,5 cases were treated with targeted therapy drugs.7.5 ml peripheral blood samples from these patients were collected and saved in test tube at the temperature of 15 ℃-30 ℃.The tests had to be done within 96 hrs after the blood sample drawn.We selected fluorescent anti-CKS/18/19 antibodies as CTC makers for renal cell carcinoma.Then the number of CTC was quantitative detected by CSS.The feasibility and detection rate of testing CTC in patients with RCC by CSS was evaluated,and the improvement of method was discussed.Results Quantitative test results of CTC in 8 patients with renal cell carcinoma were negative.25 CK+CD45 + double positive cells were found in one T4N0M1 patient's peripheral blood.The detection rate of the CTC in TNM stage T3N0M0 and T4N0M1 renal cell carcinoma patients using CSS with epithelial tumor cell maker anti-CK8/18/19 was zero.Conclusions Anti-CK8/18/19 antibodies can not be used in testing circulating tumor cells in patients with renal cell carcinoma by Cell-search System.
